Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

CB-839
Read More
Cancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine in this biochemical pathway, thereby reducing cell proliferation and tumor growth.
March 6, 2019
Find out more
Zaltrap
Read More
Zaltrap is a human recombinant fusion protein comprising segments of the human VEGFRs 1 and 2
and the Fc portion of the human immunoglobulin G1 (Tang et al., 2008).
January 19, 2016
Find out more
Vraylar
Read More
Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor.
March 29, 2018
Find out more
Stelara
Read More
Stelara (ustekinumab; Johnson & Johnson/Mitsubishi Tanabe) is a high-affinity, fully human monoclonal antibody that targets the p40 subunit of cytokines interleukin (IL)-12 and IL-23 proteins that occur in the immune system.
August 2, 2018
Find out more
Respiratory Care: Mechanical Ventilators and Pulmonary Function Testing Systems

$4,750.00

Asthma and COPD affect an estimated 590 million people worldwide, with an additional 114 million affected by COVID-19 from March 2020 to March 2021. Devices used in the diagnosis and treatment of these and other respiratory disorders include mechanical ventilators and pulmonary function testing systems.
March 30, 2021
Find out more
Idalopirdine
Read More
Idalopirdine (Lundbeck/Otsuka) is an active, potent, and selective oral 5-hydroxytryptamine-6 receptor antagonist.
September 2, 2016
Find out more
Chronic Lymphocytic Leukemia (CLL)
Read More
The CLL treatment paradigm has changed significantly over the past five years, with targeted therapies such as Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors displacing chemotherapy-based treatments for most patients who have CLL.
October 4, 2022
Find out more
Singulair
Read More
Singulair (montelukast; Merck & Co/Kyorin) is an oral leukotriene D4 receptor antagonist used for prophylactic treatment of asthma. The drug is available in several oral formulations and is primarily taken as an add-on therapy for patients with refractory and/or allergic asthma.
February 16, 2018
Find out more
When Deals Go Wrong: Lessons from Failure

$2,995.00

Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Yet a look back at prior years’ eye-popping deal sums reveals many billions of dollars of write-offs and lost value. Key assets failed or disappointed in at least half of 2014’s largest acquisitions and licensing deals. Failure is part of the drug discovery landscape, but some lessons can be learned from dud deals.

July 12, 2019
Find out more
Ophthalmic Surgical Products Market

$4,750.00

At $9.1bn, the ophthalmic surgical products market is one of the largest medical device markets globally, and serves an important need: preventing blindness for millions of people who suffer from cataracts, glaucoma, vitreoretinal disease, and refractive errors.
December 8, 2021
Find out more
Immuno-Oncology Deal Trends, 2012–16

$2,995.00

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.
April 19, 2017
Find out more
Congestive Heart Failure Pulse Survey

$599.00

The study was just closed early, as LCZ696 increased time to first occurrence of either

cardiovascular death or heart failure hospitalization, though details have not been released.

We surveyed 10 US Cardiologists to get a preview of how they would use LCZ696 under different

assumptions about what the study found.
April 1, 2014
Find out more
Diabetes Management: Insulin Pumps Market (2022)

$4,750.00

In 2021, global sales of insulin pumps and related items were estimated at nearly $3.5bn. Market drivers include technological advancements such as the development of easy to wear pod-based designs and predictive software, the expanding use of insulin pumps as an alternative to syringe-based insulin delivery, an ever-increasing population of individuals requiring insulin drug delivery, and a significant disposables aftermarket. Market limiters include restrained healthcare spending in some countries due to slowed economic growth combined with a high per unit cost for insulin pumps. Additionally, supply chain disruptions as a result of the Russian invasion of Ukraine, and a shortage of shipping containers have constrained growth. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for automated insulin pumps and related accessories. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2021–26.
August 25, 2022
Find out more
Chronic Heart Failure KOL Interview – Germany

$599.00

This interview with a Germany-based key opinion leader (KOL) provides insights into patient segmentation, as well as prescribing trends for key marketed brands and late-phase pipeline therapies for chronic heart failure (CHF). Marketed brands discussed include Entresto, Farxiga, Jardiance, Corlanor, and Verquvo, while pipeline therapies highlighted are omecamtiv mecarbil, Zynquista, Invokana, Kerendia, Furoscix, and Revascor.
August 15, 2022
Find out more
Early Access to Medicines in the US and Europe

$2,995.00

Faced with pressure from stakeholders – particularly patients – governments, regulators, and some countries have introduced new options and/or processes to speed up access to medicines. This includes access before marketing authorization, and speeding up the marketing authorization, or less often, the health technology assessment processes.

July 15, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *